Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
C I Naturmega S A is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is assigned to 1 distinct examiner, VAJDA, KRISTIN ANN, and is located within 1 distinct art unit. This represents a very focused prosecution profile, where all active engagement with the USPTO is channeled through a single point of contact. The concentration in 1 distinct art unit suggests that the technology being patented falls into a specific niche within the broader Biotechnology & Pharmaceuticals field.
VAJDA, KRISTIN ANN is the busiest examiner for this portfolio, currently managing 1 pending office action. Because there is only 1 pending office action in the entire portfolio, this examiner's role is central to the company's immediate patent goals. For practitioners, this means that the strategy is entirely dependent on the feedback from VAJDA, KRISTIN ANN. There are no other pending actions or examiners to provide a comparative baseline for prosecution within this technology area. Success for C I Naturmega S A in this instance relies on successfully addressing the specific concerns raised in the 1 pending office action within its designated art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAJDA, KRISTIN ANN | 1 | 83.8% | +11.2% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18399352 | SYNTHESIS OF VITAMIN D3 FROM CHOLESTEROL EXTRACTED FROM FISH OIL | VAJDA, KRISTIN ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18399352 | SYNTHESIS OF VITAMIN D3 FROM CHOLESTEROL EXTRACTED FROM FISH OIL | VAJDA, KRISTIN ANN | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18399352 | SYNTHESIS OF VITAMIN D3 FROM CHOLESTEROL EXTRACTED FROM FISH OIL | VAJDA, KRISTIN ANN | 1622 | §112 | Non-Final OA | — | Pending | Dec 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialC I Naturmega S A has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Kristin Ann Vajda has the most, with 1 of C I Naturmega S A's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.